Literature DB >> 16256790

Efficient myocyte gene delivery with complete cardiac surgical isolation in situ.

Charles R Bridges1, Kapil Gopal, David E Holt, Charles Yarnall, Steven Cole, Rochelle B Anderson, Xiaoqing Yin, Anthony Nelson, Benjamin W Kozyak, Zhonglin Wang, James Lesniewski, Leonard T Su, Danielle M Thesier, Hari Sundar, Hansell H Stedman.   

Abstract

BACKGROUND: Previously, we used cardiopulmonary bypass with incomplete cardiac isolation and antegrade administration of vector for global cardiac gene delivery. Here we present a translatable cardiac surgical procedure that allows for complete surgical isolation of the heart in situ with retrograde (through the coronary venous circulation) administration of both vector and endothelial permeabilizing agents to increase myocyte transduction efficiency.
METHODS: In 6 adult dogs the heart was completely isolated with tourniquets placed around both vena cavae and cannulas and all pulmonary veins. On cardiopulmonary bypass, the aorta and pulmonary artery were crossclamped, and the heart was isolated. Crystalloid cardioplegia at 4 degrees C containing 10(13) particles of adenovirus encoding LacZ and 15 microg of vascular endothelial growth factor was infused retrograde into the coronary sinus and recirculated for a total of 30 minutes. The dogs were then weaned from cardiopulmonary bypass and allowed to recover. With a catheter, 3 control dogs underwent retrograde infusion of the same cocktail without cardiac isolation or cardiopulmonary bypass.
RESULTS: Beta-galactosidase activities in the cardiopulmonary bypass group were several orders of magnitude higher in both the right and left ventricles when compared with those in the control group (P < .05). X-gal staining from the cardiopulmonary bypass group showed unequivocal evidence of myocyte gene expression globally in a significant proportion of cardiac myocytes. No myocyte gene expression was observed in the control group.
CONCLUSION: A novel cardiac surgical technique has been developed. This approach with cardiac isolation and retrograde delivery of vector through the coronary sinus results in efficient myocyte transduction in an adult large animal in vivo.

Entities:  

Mesh:

Year:  2005        PMID: 16256790     DOI: 10.1016/j.jtcvs.2005.07.035

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

Review 1.  Cardiac gene therapy: from concept to reality.

Authors:  Razmig Garo Kratlian; Roger J Hajjar
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 2.  Delivery of gene and cellular therapies for heart disease.

Authors:  Justin A Mariani; David M Kaye
Journal:  J Cardiovasc Transl Res       Date:  2010-05-11       Impact factor: 4.132

Review 3.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 4.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

Review 5.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

Review 6.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 7.  Rescuing the failing heart by targeted gene transfer.

Authors:  Yoshiaki Kawase; Dennis Ladage; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2011-03-08       Impact factor: 24.094

Review 8.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

9.  Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo.

Authors:  J D White; D M Thesier; J B D Swain; M G Katz; C Tomasulo; A Henderson; L Wang; C Yarnall; A Fargnoli; M Sumaroka; A Isidro; M Petrov; D Holt; R Nolen-Walston; W J Koch; H H Stedman; J Rabinowitz; C R Bridges
Journal:  Gene Ther       Date:  2011-01-13       Impact factor: 5.250

10.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.